Table 1.
Classes of PI3K pathway inhibitors
| Class | Drug target(s) | Drugs | Selected toxicities by class |
|---|---|---|---|
| Pan-PI3K inhibitors | All class IA PI3Ks | Buparlisib (BKM120) | Hyperglycemia |
| Pilaralisib (XL147) | Rash | ||
| Pictilisib (GDC-0941) | Neutropenia | ||
| Neuropsychiatric effects (confusion, depression, anxiety) | |||
| Hepatotoxicity | |||
| Diarrhea | |||
| Isoform-specific PI3K inhibitors | PI3K p110α isoform | Alpelisib (BYL719) | Hyperglycemia |
| Taselisib (GDC-0032) | Rash | ||
| Diarrhea | |||
| Pneumonitis | |||
| PI3K p110δ isoform | Idelalisib (CAL-101) | Myelosupression | |
| Duvelisib (IPI-145) | Hyperglycemia | ||
| Rash | |||
| Diarrhea | |||
| Hypertension | |||
| Pan-Akt inhibitors | Three isoforms of Akt (Akt1, 2, and 3) | Capivasertib (AZD5363) | Rash |
| Ipatasertib (GDC0068) | Hyperglycemia | ||
| MK2006 | |||
| mTORC1 (mammalian target of rapamycin complex 1) inhibitors | mTORC1 kinase | Everolimus | Stomatitis |
| Temsirolimus | Rash | ||
| Deforolimus | Pneumonitis | ||
| Hyperglycemia | |||
| Immunosuppression | |||
| Dual PI3K and mTOR inhibitors | p110 subunit of PI3K and mTOR | Dactolisib (BEZ235) Voxtalisib (XL765) | Stomatitis |
| SF1126 | Hyperglycemia | ||
| GSK1059615 | Immunosuppression |